Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies Expands Research Division and Announces Dr. Sergei Svarovsky as Chief Scientific Officer of Subsidiary Sapphire Biotech
SAN DIEGO, May 28, 2020 /PRNewswire/ -- Medical Marijuana, Inc.. (OTC: MJNA) (the "Company"), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its investment company AXIM® Biotechnologies, Inc. (OTCQB: AXIM) ("AXIM® Biotech" or "AXIM") has expanded its research division through the establishment of a state-of-the-art laboratory in the biotechnology industry hub of San Diego, Calif. Additionally, respected scientist Dr. Sergei Svarovsky will lead the oncology-focused research team as the Chief Scientific Officer and founder of AXIM's subsidiary, Sapphire Biotech, Inc. ("Sapphire"). "This new laboratory is a giant step forward for AXIM to bring its research completely in-house and continue its scientific discoveries at an accelerated pace," said Dr. Stuart Titus, CEO of Medical Marijuana, Inc. "We are excited to see further innovations from the team to be led by well-recognized researcher, Dr. Svarovsky." AXIM's new research laboratory is fully equipped for all research to be done by its own research team and sits adjacent to many of the world's largest biotechnology companies. This location, as well as the density of biotechnology companies in the area, grants AXIM the ability to increase the speed and access of its research due to nearby analytical services and vital chemistry and biology equipment. Dr. Sergei Svarovsky has been appointed as Chief Scientific Officer to oversee this new lab and lead Sapphire's research and product development efforts. He holds a Master of Science in Physical Chemistry from Novosibirsk State University, a Doctor of Philosophy in Physical Organic Chemistry and a Master of Business Administration from West Virginia University. As a Research Fellow at the National Institute of Health's (NIH) National Cancer Institute, Dr. Svarovsky's novel innovations earned him the prestigious NIH Fellow Award for Research Excellence (FARE). "AXIM recently pivoted into an exciting new oncology-focused company. Through this new lab and Dr. Svarovsky's leadership, we aim to provide our talented research team with state-of-the-art research resources to continue making amazing discoveries," said AXIM® Biotech CEO John W. Huemoeller II. For more information about AXIM, please visit www.aximbiotech.com. About AXIM® Biotechnologies Currently, Sapphire Biotech, Inc.'s diagnostic tool is being used to study the company's enzyme biomarker to detect pancreatic cancer earlier than circulating tumor cells. Learn more here. For more information, please visit www.AXIMBiotech.com. About Medical Marijuana, Inc. Medical Marijuana, Inc.'s headquarters is in San Diego, California, and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com. To see Medical Marijuana, Inc.'s corporate video, click here. Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.'s shop. FORWARD-LOOKING DISCLAIMER FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE LEGAL DISCLOSURE CONTACT: Investor Relations Contact: SOURCE Medical Marijuana, Inc. |
||
Company Codes: OTC-PINK:MJNA, OTC-PINK:AXIM, OTC-QB:AXIM, OtherOTC:AXIM, OtherOTC:MJNA |